Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats. (25th July 2015)

• Record Type: Journal Article
• Authors: Krishnamurthy, Bhaskar; Rani, Neha; Bharti, Saurabh; Golechha, Mahaveer; Bhatia, Jagriti; Nag, Tapas Chandra; Ray, Ruma; Arava, Sudheer; Arya, Dharamvir Singh
• Is Part Of: Chemico-biological interactions. Volume 237(2015)
• Page Start: 96
• Page End: 103
• Publication Date: 2015-07-25
• Subjects: Febuxostat -- Carvedilol -- Doxorubicin -- Cardiotoxicity -- Xanthine oxidase -- Antioxidant; Biochemistry -- Periodicals; Toxicological chemistry -- Periodicals; Biochemistry -- Periodicals; Biologie moléculaire -- Périodiques; Biochimie -- Périodiques; Toxicologie biochimique -- Périodiques; 572
• DOI: 10.1016/j.cbi.2015.05.013
• Languages: English
• ISSNs: 0009-2797

Abstract

Highlights: Concomitant administration of febuxostat mitigated doxorubicin-induced cardiotoxicity. This was due to its anti-oxidant, anti-inflammatory and anti-apoptotic effect. The activity of febuxostat in blocking doxorubicin induced cardiotoxicity was similar to that observed with carvedilol. Abstract: The clinical use of doxorubicin is associated with dose limiting cardiotoxicity. This is a manifestation of free radical production triggered by doxorubicin. Therefore, we evaluated the efficacy of febuxostat, a xanthine oxidase inhibitor and antioxidant, in blocking cardiotoxicity associated with doxorubicin in rats. Male albino Wistar rats were divided into four groups: control (normal saline 2.5 mL/kg/day i.p. on alternate days, a total of 6 doses); Doxorubicin (2.5 mg/kg/day i.p. on alternate days, a total of 6 doses), Doxorubicin + Febuxostat (10 mg/kg/day oral) and Doxorubicin + Carvedilol (30 mg/kg/day oral) for 14 days. Febuxostat significantly ameliorated the doxorubicin-induced deranged cardiac functions as there was significant improvement in arterial pressures, left ventricular end diastolic pressure and inotropic and lusitropic states of the myocardium. These changes were well substantiated with biochemical findings, wherein febuxostat prevented the depletion of non-protein sulfhydryls level, with increased manganese superoxide dismutase level and reduced cardiac injury markers (creatine kinase-MB and B-type natriuretic peptide levels) and thiobarbituric acid reactive substances level. Febuxostat also exhibited significant anti-inflammatory (decreased expression of NF-κBp65, IKK-β and TNF-α) and anti-apoptotic effect (increased Bcl-2 expression and decreased Bax and caspase-3 expression and TUNEL positivity). Hematoxylin and Eosin, Masson Trichome, Picro Sirius Red and ultrastructural studies further corroborated with hemodynamic and biochemical findings showing that febuxostat mitigated doxorubicin-induced increases in inflammatory cells, edema, collagen deposition, interstitial fibrosis, perivascular fibrosis and mitochondrial damage and better preservation of myocardial architecture. In addition, all these changes were comparable to those produced by carvedilol. Thus, our results suggest that the antioxidant and anti-apoptotic effect of febuxostat contributes to its protective effects against doxorubicin-induced cardiotoxicity.